- Home
- OI vs RCKT Comparison
OI vs RCKT Comparison
Compare OI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | RCKT |
|---|---|---|
| Founded | 1903 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 394.2M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OI | RCKT |
|---|---|---|
| Price | $6.52 | $3.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $15.29 | ★ $29.73 |
| AVG Volume (30 Days) | ★ 3.2M | 1.4M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $6,426,000,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $1.88 | $64.28 |
| P/E Ratio | ★ N/A | $5.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.35 | $2.53 |
| 52 Week High | $16.91 | $5.45 |
Technical Indicators
Market Signals| Indicator | OI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 53.35 |
| Support Level | N/A | $3.32 |
| Resistance Level | $9.63 | $3.65 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 11.79 | 70.73 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.